Depression News and Research

Latest Depression News and Research

Male abuse victims more likely to suffer from psychological trauma

Men who are abused by their female partners can suffer significant psychological trauma, such as post-traumatic stress disorder, depression and suicidal thoughts, according to two new papers published by the American Psychological Association.

8 Apr 2011

Study suggests depression treatment may have long-term benefits

Ian Colman, an epidemiologist in the School of Public Health at the University of Alberta, recently completed a study that suggests that treatment of depression may have long-term benefits.

8 Apr 2011

Study: DBS surgery allows 77% of patients to stop anti-tremor medication use

Deep brain stimulation, a surgical procedure to suppress faulty nerve signals, allowed 77 percent of patients to stop the medications used to treat their essential tremors within one year following the surgery, University of South Florida researchers report.

8 Apr 2011

Patients with stroke can benefit from antidepressants

A University of Iowa study finds that patients treated with a short course of antidepressants after a stroke have significantly greater improvement in physical recovery than patients treated with a placebo.

8 Apr 2011

Neuralstem to present HSSC Phase I trial data in amyotrophic lateral sclerosis at AAN meeting

Neuralstem, Inc. announced that the Phase I safety trial of its human spinal cord stem cells in amyotrophic lateral sclerosis is the subject of three presentations at the American Academy of Neurology Annual Meeting, April 9-16th, in Honolulu, HI.

7 Apr 2011

Cliffside encourages patients to continue antidepressant use despite health risks

Cliffside Malibu, one of America's leading drug and alcohol treatment centers, is strongly urging its patients who are currently taking antidepressants not to stop, despite a new study and subsequent media reports that such drugs could raise the risk of heart attack or stroke in middle-age men taking the medications.

7 Apr 2011

Supplements are less well regulated than drugs and may have side effects, drug interactions and toxicities

Vitamins, herbs and other dietary supplements are sold as natural alternatives to pharmaceuticals and many people turn to them in an attempt to improve their health. Others seek supplements to lose weight or after hearing that they can help with serious medical conditions.

7 Apr 2011

New insight into Huntington's disease

Huntington's disease has long been linked to jerky movements. Now, researchers in Lund, Sweden, have shown that the metabolism can also be seriously affected by the hereditary disease. The new laboratory findings provide hope of entirely new treatment methods.

7 Apr 2011

FDA approves Horizant Extended-Release Tablets for Restless Legs Syndrome

GlaxoSmithKline and XenoPort, Inc. announced Wednesday that the U.S. Food and Drug Administration (FDA) has approved Horizant™ (gabapentin enacarbil) Extended-Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome in adults. Horizant is not recommended for patients who are required to sleep during the daytime and remain awake at night.

7 Apr 2011

Work, social and family disability affect 50% of patients with bipolar disorder

Such was the conclusion obtained in a study conducted at the University of Granada that was recently awarded a prize in the IV Spain-Portugal Meeting on Therapeutical Adherence held in Oporto.

6 Apr 2011

New medical guidelines for diabetes care

Today the American Association of Clinical Endocrinologists released new medical guidelines for developing comprehensive care plan for management of diabetes mellitus.

6 Apr 2011

Major depression linked to premature aging of immune cells: Study

Certain cases of major depression are associated with premature aging of immune cells, which may make people more susceptible to other serious illness, according to findings from a new UCSF-led study.

6 Apr 2011

Huntingtin protein is responsible for metabolic imbalances in hypothalamus

In Huntington's disease, the mutant protein known as huntingtin leads to the degeneration of a part of the brain known as the basal ganglia, causing the motor disturbances that represent one of the most defining features of the fatal disease.

6 Apr 2011

National Alliance for Research on Schizophrenia and Depression is now Brain & Behavior Research Foundation

The Brain & Behavior Research Foundation (formerly NARSAD, the National Alliance for Research on Schizophrenia and Depression) continues its 25-year mission to alleviate the suffering of mental illness by awarding grants that will lead to advances and breakthroughs in scientific research.

5 Apr 2011

Mexican-born migrants may face high risk of developing depressive, anxiety disorders

People who migrate to the United States from Mexico have a significantly higher risk of developing depressive or anxiety disorders than family members of migrants who remain in Mexico, according to a report in the April issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

5 Apr 2011

Curis presents vismodegib Phase II data in basal cell nevus syndrome at AACR meeting

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of interim Phase II clinical data on Hedgehog pathway inhibitor vismodegib in patients with basal cell nevus syndrome, which is also commonly referred to as Gorlin syndrome.

5 Apr 2011

Long hours at work damages heart: Study

According to British scientists, people who regularly work long hours may be significantly increasing their risk of developing heart disease that could eventually kill them.

5 Apr 2011

Promising results for new depression treatment

A new, non-invasive treatment for depression that delivers barely perceptible electric currents to the scalp has had promising results in a Sydney trial, and researchers are now looking for participants for a follow up study.

4 Apr 2011

Avanir files IND for NUEDEXTA/AVP-923 Phase II clinical trial for central neuropathic pain in MS patients

Avanir Pharmaceuticals, Inc. today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a large Phase II clinical trial of AVP-923, an investigational drug for the treatment of central neuropathic pain in patients with multiple sclerosis (MS). The FDA has acknowledged receipt of the submission and the company expects that the IND filing will be subject to standard 30-day review.

4 Apr 2011

Abbott and Enanta's ABT-450/r Phase 2 study results against HCV presented at EASL meeting

Abbott and Enanta Pharmaceuticals today announced 12-week results from a Phase 2 study of ABT-450/r, an investigational, oral protease inhibitor being developed for the treatment of hepatitis C infection.

4 Apr 2011

Depression News and Research

Latest Depression News and Research

Male abuse victims more likely to suffer from psychological trauma

Study suggests depression treatment may have long-term benefits

Study: DBS surgery allows 77% of patients to stop anti-tremor medication use

Patients with stroke can benefit from antidepressants

Neuralstem to present HSSC Phase I trial data in amyotrophic lateral sclerosis at AAN meeting

Cliffside encourages patients to continue antidepressant use despite health risks

Supplements are less well regulated than drugs and may have side effects, drug interactions and toxicities

New insight into Huntington's disease

FDA approves Horizant Extended-Release Tablets for Restless Legs Syndrome

Work, social and family disability affect 50% of patients with bipolar disorder

New medical guidelines for diabetes care

Major depression linked to premature aging of immune cells: Study

Huntingtin protein is responsible for metabolic imbalances in hypothalamus

National Alliance for Research on Schizophrenia and Depression is now Brain & Behavior Research Foundation

Mexican-born migrants may face high risk of developing depressive, anxiety disorders

Curis presents vismodegib Phase II data in basal cell nevus syndrome at AACR meeting

Long hours at work damages heart: Study

Promising results for new depression treatment

Avanir files IND for NUEDEXTA/AVP-923 Phase II clinical trial for central neuropathic pain in MS patients

Abbott and Enanta's ABT-450/r Phase 2 study results against HCV presented at EASL meeting

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Depression News and Research

Latest Depression News and Research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in